

PROHOST  FILTER

▲ UP: EYET - OSIP - GENZ TEMPORARY DOWN ▼ : GERN

GERON: Early Friday, Geron Corp. (**GERN**) reported that its previously announced underwritten public offering of six million shares of common stock was priced at \$9.00 per share. The company noted that the public offer would be closed on September 21, 2005 and the gross price from this underwritten public offering would be \$54 million. Click on ([news](#)),

Merck & Co, Inc. (MRK) would exercise a warrant to purchase share of Geron common stock with a total exercise price of **\$18.0 million at \$9.00 per share**. The warrant was issued to Merck at the time of collaboration and license agreement entered by Geron and Merck on July 15, 2005.

Prohost Comments: It is obvious that the stock should be subjected to selling, yet, our strategy is that as long as the scientific programs and the product pipeline are not at the origin of the stock decline, we take advantage of the dip and accumulate. We love this firm's technology and value its patents and products.

EYETECH (EYET): The Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has issued a positive opinion **recommending approval of Macugen** for the treatment of neovascular age-related macular degeneration.

Good news for Osi (OSIP) too, which decided to take-over Eyetech. Besides the product and its new recommended approval, Osi was after Eyetech technology (Toll-like receptor), which contributed to the making of Macugen and is surfacing as the one of the most promising technologies for drug discovery, design and development.

GENZYME (GENZ) and Schering AG announced interim results from a Phase 2 trial comparing Campath with Rebif for the treatment of multiple sclerosis. The results showed a large treatment effect in favor of Campath. See ([news](#)). **This is Good news and the stock is reacting.**

PROHOST RESEARCH**P.O.BOX 640 429****Oakland Gardens, Ny 11364****Telephone : 516 678 1335****Fax 718 423 2731***E-mail prohost@aol.com.*

FORWARD-LOOKING STATEMENT Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: <http://www.sec.gov/consumer/cyberfr.htm>